- Home
- TCRX vs STTK Comparison
TCRX vs STTK Comparison
Compare TCRX & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- STTK
- Stock Information
- Founded
- TCRX 2018
- STTK 2016
- Country
- TCRX United States
- STTK United States
- Employees
- TCRX N/A
- STTK N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- STTK Health Care
- Exchange
- TCRX Nasdaq
- STTK Nasdaq
- Market Cap
- TCRX 91.7M
- STTK 83.8M
- IPO Year
- TCRX 2021
- STTK 2020
- Fundamental
- Price
- TCRX $1.60
- STTK $1.94
- Analyst Decision
- TCRX Strong Buy
- STTK Hold
- Analyst Count
- TCRX 5
- STTK 6
- Target Price
- TCRX $9.40
- STTK $2.67
- AVG Volume (30 Days)
- TCRX 219.1K
- STTK 1.6M
- Earning Date
- TCRX 11-11-2025
- STTK 11-13-2025
- Dividend Yield
- TCRX N/A
- STTK N/A
- EPS Growth
- TCRX N/A
- STTK N/A
- EPS
- TCRX N/A
- STTK N/A
- Revenue
- TCRX $6,961,000.00
- STTK $2,997,000.00
- Revenue This Year
- TCRX $255.18
- STTK N/A
- Revenue Next Year
- TCRX N/A
- STTK N/A
- P/E Ratio
- TCRX N/A
- STTK N/A
- Revenue Growth
- TCRX N/A
- STTK N/A
- 52 Week Low
- TCRX $1.02
- STTK $0.69
- 52 Week High
- TCRX $6.23
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- TCRX 36.40
- STTK 64.83
- Support Level
- TCRX $1.73
- STTK $1.68
- Resistance Level
- TCRX $1.96
- STTK $2.01
- Average True Range (ATR)
- TCRX 0.11
- STTK 0.23
- MACD
- TCRX -0.03
- STTK 0.05
- Stochastic Oscillator
- TCRX 0.00
- STTK 80.82
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.